Compare Summit Therapeutics Inc (SMMT) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs United States Oil ETF — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while United States Oil ETF trades at $147.87 (market cap $1.90B). The key difference: Summit Therapeutics Inc is far larger — about 7.2× United States Oil ETF's market cap, and United States Oil ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and United States Oil ETF for 21 Days on average.
| SMMT | USO | |
|---|---|---|
Market Cap | $13.71B | $1.90B |
Volume | 6,173,057 | 5,932,922 |
Sector | Health | — |
52-Week High | $26.38 | $161.86 |
52-Week Low | $12.43 | $66.17 |
Typical Hold Time | 16 Days | 21 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
USO is trading at $148.32, up 3.06% today with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings with RSI at 63.03 suggesting balanced momentum. Recent news highlights oil market volatility from Middle East tensions and OPEC+ production decisions, creating both supply risks and price pressures.
The outlook remains cautiously optimistic given geopolitical tensions supporting oil prices, though G7 reserve releases and potential supply disruptions create conflicting forces. Key resistance sits at $150 with support at $146, making current levels critical for near-term direction amid volatile energy market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
